The feasibility of giving i.v. or hepatic arterial infusion of high dose Mitomycin C (HDMMC) followed by autologous bone marrow transplant was studied in 4 patients with metastatic tumour in the liver. Doses ranged from 40-50 mg m-2. The dose limiting toxicity of Mitomycin C is myelosuppression. High dose Mitomycin C has been given i.v. followed by autologous bone marrow transplantation with complete haematological recovery (Champlin, 1980; DiStefano, 1980; Sarna, 1980) . Autologous bone marrow transplant accelerates haematological recovery (DiStefano, 1980) . Non-haematological toxicity has been nausea, vomiting, diarrhoea, hepatotoxicity (veno-occlusive pathology), haemorrhagic pancreatitis, pleuropericarditis, severe stomatitis, and severe haemorrhagic enterocolitis with doses of 20-40mg m-2 day-1 x 3 days (DiStefano, 1980) . Intra-arterial infusion of chemotherapy has two theoretical advantages over i.v. infusion: achievement of a higher drug concentration in the tumour bearing region and potential for a substantial uptake of the drug by the tumour in its first passage which might reduce excessive peripheral toxicity (Chen, 1980) . A clinical pharmacological study with Mitomycin C confirms these theoretical advantages (Hashimoto, 1978) . Intra-arterial infusion of Mitomycin C in conventional dosage has been used to treat bronchial and hepatic tumours (Hellekant, 1978; Patt, 1981) .
All patients gave written informed consent to the procedure. The first patient had high dose Mitomycin C (HDMMC) i.v., the second had half the dose i.v. and half by hepatic arterial infusion simultaneously. The third and fourth had HDMMC by hepatic arterial infusion alone. Two patients had breast adenocarcinoma metastatic to liver and bone, refractory to therapy, one had rectal adenocarcinoma metastatic to liver and one had cholangiocarcinoma extensively invading the liver. The first two patients had been extensively pretreated and the second two were previously untreated. The mean age was 33 years (24-40) and their performance status ranged from 20-100% (Karnofsky Performance Status), but they all had normal cardiopulmonary and renal function. Bone marrow was collected from the posterior iliac crests at least 4-weeks after any chemotherapy, cryopreserved and stored in liquid nitrogen (Gilmore, 1983) . Mitomycin C was given as a single dose of 40-50 mg m L2 Iv. infusion was over 45 min through a central venous line. Hepatic arterial infusion was via a catheter placed percutaneously into the femoral artery and introduced into the hepatic artery. Mitomycin C was diluted 1 mg to 10ml of normal saline and infused under pressure (using a pressure bag), 45-60 min. Patients were nursed in single rooms and given non-absorbable antibiotics and cotrimoxazole. They were nursed in reverse barrier isolation whilst they were neutropenic (neutrophils <1.0 x 1091 -1). Platelet infusions were given as required. The infused bone marrow was stored between 1-7 months prior to infusion. It was rapidly thawed and infused 48 hours after the Mitomycin C. An average of 1.2 x 108 nucleated cellskg-1 and 8700 CFU-GM kg -I body wt was infused.
Complete None of the patients became infected. It would appear feasible to be able to give high dose Mitomycin C (50mgm-2) safely as a single hepatic arterial infusion followed by autologous bone marrow transplantation to accelerate haematological recovery to relatively young patients with normal cardiopulmonary and renal function who have metastatic liver cancer. We have not studied the pharmokinetics of intra-arterial infusion of Mitomycin C and so it is uncertain as to whether there is a definite advantage for drug delivery to the tumour by this route. However, there was a high response rate in this small group of patients with resistant tumours and it seems likely that a high concentration of Mitomycin C would have been delivered to the tumour. The duration of this high concentration might be prolonged by inflating a balloon catheter for a short period of time in the inferior vena cava proximal to the hepatic venous drainage delaying perfusion of the drug. However, arterial reflux may prove a problem with this technique. We feel that i.v. and hepatic intra-arterial infusion of high dose Mitomycin C with autologous bone marrow rescue merits further study to ascertain whether there is increased hepatic uptake of Mitomycin C by the intra-arterial route, whether this confers a therapeutic advantage over the intravenous route, and to further evaluate the role of autologous bone marrow transplant in this setting and to further evaluate high dose Mitomycin C as treatment of cancer metastatic to the liver. 
